Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Delayed Diagnosis and Diagnostic Imprinting in Pediatric CNS Tumors:…

Ibrahim Qaddoumi

cfDNA for Liquid Biopsy for Patients With Glioblastoma

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Bagley

2024 Neuro-Oncology Update: Brain Tumors

Scripps Health

T. McGranahan

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Overview and Updates in Brain Tumors

Henry Friedman

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

Key Metastatic NSCLC Trial Updates Including MARIPOSA and FLAURA2

Yale Cancer Center

S. Goldberg

Best Practices for the Provider Approach in Treating Patients With I…

Katherine Peters

RANO 2.0 and Advances in Neuroimaging: Impact on Clinical Trials and…

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Mohan

Management of Stage IV NSCLC With Actionable Mutations

Integrity CE

G. Dy

Treatment Strategies for Metastatic HER2-Mutant NSCLC

UNC Lineberger Comprehensive Cancer Center

S. Patel

Effective Strategies for Managing IDH-Mutant Gliomas

Matteo Simonelli

Cemiplimab Monotherapy as 1L Treatment for Advanced NSCLC: EMPOWER-L…

ecancer

A. Baramidze

WCLC 2024 Insights: Biology of CNS Metastases in NSCLC

Insights from 2024 WCLC

T. Burns

Neoadjuvant Chemoimmunotherapy in Unresectable NSCLC

MI&T Congressi

I. Opitz